title: CA 19-9 and survival in advanced and unresectable pancreatic adenocarcinoma and cholangiocarcinoma.
abstract: BACKGROUND
  The CA 19-9 tumour marker is increasingly used to monitor response to therapy in patients with pancreatic adenocarcinoma. Serum CA 19-9 levels have also been shown to correlate with survival. However, their role in cholangiocarcinoma is less clear.
  
  
  OBJECTIVE
  To assess the utility of CA 19-9 levels in the management of patients with advanced pancreatic adenocarcinoma or cholangiocarcinoma in routine clinical practice is the aim of the study.
  
  
  METHODS
  A retrospective analysis of CA 19-9 values and survival was performed in 26 patients with pancreatic adenocarcinoma receiving gemcitabine and in 18 patients with cholangiocarcinoma.
  
  
  RESULTS
  Patients with advanced pancreatic adenocarcinoma receiving gemcitabine who experienced a decrease of > or = 20% in CA 19-9 concentration had a median survival of 13.9+ months (range 4.2-23.5) compared to 7.6+ months (range 4.0-14.7) in those without such a change (p = 0.0109). In patients with advanced cholangiocarcinoma, the median survival was longest in those with a baseline CA 19-9 level of less than 1,000 U/ml; 11.8 months (range 1.0-41.4) vs 6.2 months (range 3.1-9.4; p = 0.0075).
  
  
  CONCLUSIONS
  The CA 19-9 concentration has a valuable role in predicting outcome in patients with pancreatic adenocarcinoma and cholangiocarcinoma. It is helpful in guiding therapy and should be used accordingly in oncology practice.
authors.affiliation: Department of Cancer Medicine, Ninewells Hospital, Dundee, DD1 9SY, UK. clintonali@nhs.net
authors.forename: Clinton W
authors.initials: CW
authors.lastname: Ali
authors.forename: Thomas F
authors.initials: TF
authors.lastname: Kaye
authors.forename: Douglas J A
authors.initials: DJ
authors.lastname: Adamson
authors.forename: Iain S
authors.initials: IS
authors.lastname: Tait
authors.forename: Francesco M
authors.initials: FM
authors.lastname: Polignano
authors.forename: Martin S
authors.initials: MS
authors.lastname: Highley
mesh_terms: D000230:Adenocarcinoma / Q000097:blood / Q000188:drug therapy / Q000401:mortality*; D000368:Aged; D000369:Aged, 80 and over; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D001650:Bile Duct Neoplasms / Q000097:blood / Q000188:drug therapy / Q000401:mortality*; D001653:Bile Ducts, Intrahepatic / Q000473:pathology; D014408:Biomarkers, Tumor / Q000097:blood; D018395:CA-19-9 Antigen / Q000097:blood*; D018281:Cholangiocarcinoma / Q000097:blood / Q000188:drug therapy / Q000401:mortality*; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010190:Pancreatic Neoplasms / Q000097:blood / Q000188:drug therapy / Q000401:mortality*; D011379:Prognosis; D012189:Retrospective Studies; D015996:Survival Rate; D016896:Treatment Outcome; D000093542:Gemcitabine
chemical_list: D000964:Antimetabolites, Antineoplastic; D014408:Biomarkers, Tumor; D018395:CA-19-9 Antigen; D003841:Deoxycytidine; D000093542:Gemcitabine